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Abstract 
Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease 
in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study 
was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel 
(Simparica  Trio®) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted 
concurrently to determine the infection pressure in the same areas.
Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots 
for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked 
study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 
1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological 
methods, and the percent of dogs positive for A. vasorum was calculated.
Results: In the prevention study, there were no adverse events related to treatment with Simparica  Trio®. Two 
placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs 
in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found 
positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study.
Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica  Trio®) 
was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic 
areas, A. vasorum occurrence in dogs at risk is considerable.
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Background
Angiostrongylus vasorum (also referred to as French 
heartworm) infection of dogs has been reported with 
increasing frequency in the past two decades, includ-
ing from regions outside the previously known endemic 
areas [1]. The latter include several European countries 
(e.g. France, the UK, Denmark, Ireland and Switzerland) 
[2], Newfoundland in Canada [3], Brazil, Colombia [4] 
and Uganda [1]. In most countries the occurrence has 
been historically localized to hot spots, however these 
areas where dogs are at increased risk of infection are 
expanding. For example, in the UK the endemic foci used 
to be localized in the South East of England and in South 
of Wales [5, 6] but recent reports confirmed the expan-
sion to Northern England and Scotland [7, 8]. Similarly, 
in Germany besides the historically endemic areas in the 
southwest (Baden-Wuerttemberg and Rhineland-Palat-
inate); recently, a relatively high number of cases were 
identified in the northeast (Brandenburg and Mecklen-
burg Western Pomerania) [9]. Within the endemic hot 
spots, repeated surveys showed an increasing prevalence. 
For example, in Newfoundland between 1997 and 1999 
4% of the tested dogs with cardiopulmonary disease 
were infected, while in 2000–2001, using the same inclu-
sion criteria, 24% of the tested dogs were positive for A. 
vasorum [10]. A similar trend has been reported in sev-
eral countries in Europe [11]. In Germany, a significant 
increase in the prevalence of A. vasorum  was reported 
between 2003 and 2015 [9]. Besides the historically 
endemic countries, autochthonous infections have also 
been reported in dogs from other countries including the 
Netherlands [12], Hungary [13], Slovakia [14] and Bel-
gium [15].
Computer modelling suggests that there is a high 
probability that A. vasorum will also spread in North 
America to the eastern half of the continent and 
along the western coast [16]. Indeed, the first report 
of an autochthonous A. vasorum  infection in the USA 
emerged in 2011 from a red fox in West Virginia [17]. 
In Canada the expansion has also been confirmed from 
Newfoundland and Labrador to the mainland, after the 
parasite has been isolated from coyotes in Nova Scotia 
[18]. This is not surprising given that at least five spe-
cies of European slugs which are suitable intermediate 
hosts for A. vasorum have been introduced to North 
America [19], and genetic analyses also suggested that 
A. vasorum in Newfoundland has most likely originated 
from western Europe [20].
Infections with A. vasorum may cause severe disease 
in dogs: together with the most frequently reported 
respiratory signs, bleeding diathesis, neurological signs 
and other unspecific signs are reported [21–23]. Canine 
angiostrongylosis can be fatal if left untreated [21, 23, 
24]. Dogs may be infected by ingesting the intermedi-
ate (i.e. snails and slugs) or paratenic (e.g. frogs) hosts, 
or by eating grass, chewing on sticks or drinking from 
puddles etc., that are contaminated with the third stage 
larvae excreted by the intermediate hosts [1]. In the 
final host, after visceral migration and two molts, the 
fifth-stage larvae reach the right ventricle and pulmo-
nary arteries where they develop into adults [1]. After 
mating, the females lay eggs that hatch in the respira-
tory vessels and the first-stage larvae will be excreted in 
the feces usually within two months post-infection [1].
Given the increasing number of dogs diagnosed with 
angiostrongylosis, the relevant clinical picture of the 
disease and the geographic expansion of the parasite, 
effective prophylactic medications are needed in addi-
tion to the currently approved treatments for estab-
lished infections. In the present study, the preventative 
efficacy of a novel oral combination containing mox-
idectin, sarolaner and pyrantel (Simparica  Trio®, Zoe-
tis) was evaluated in client-owned dogs. In parallel to 
this study, a prospective survey study was conducted 
concurrently to establish the contemporaneous infec-
tion pressure in the same geographical areas.
Methods
The prevention and survey studies were conducted at 
the same study sites in Denmark (16 clinics) and Italy 
(14 clinics) over a period of 14 months each. The sur-
vey study was conducted between March 2016 and May 
2017, and the prevention study between May 2016 and 
July 2017. The study sites were selected based on previ-
ous frequent diagnosis of A. vasorum infections in dogs, 
and their locations are shown in Fig. 1. Both studies com-
plied with Good Clinical Practices [25].
Prevention study
The prevention study was conducted as a double-masked, 
placebo-controlled field trial. Dogs that were at risk of 
A. vasorum infection in the opinion of the veterinarians, 
weighing at least 1.3 kg and at least 8 weeks of age were 
eligible for inclusion in the study. Dogs were considered 
to be at risk of infection if they had a history of eating 
snails/frogs, were active hunting dogs, were living or 
were walked in areas where foxes were frequently seen 
or if the household had a history of previous A. vasorum 
infection [1]. Animals that were pregnant or lactating 
or intended for breeding were excluded from the study 
as were dogs that tested positive for A. vasorum at the 
enrolment visit. Up to six dogs could be enrolled from a 
single household. Dogs were randomly allocated 1:1 to 
treatment with Simparica  Trio® or placebo according to 
a randomization plan using a randomized complete block 
design with one-way treatment structure (meaning that 
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the levels of treatment consisted of one factor of interest) 
replicated in multiple clinics.
Enrolled animals were not allowed to receive any prod-
uct with known activity for the treatment or prevention 
of A. vasorum infestation including fenbendazole, lev-
amisole, ivermectin or milbemycin oxime at any dose 
rate and via any route. Dogs that were randomized to 
the combination product group were not allowed to 
receive any medication with efficacy against fleas/ticks 
and helminths including prophylactic products against 
Dirofilaria immitis. Dogs randomized to placebo were 
only allowed to receive ectoparasiticides and anthelmin-
tics, including D. immitis preventatives (only moxidectin 
administered as a monthly oral treatment at the dose rate 
of 3 µg/kg), from the unmasked dispenser. Both groups 
were allowed to receive deltamethrin collars as mos-
quito/sand fly repellents and tapeworm treatments with 
praziquantel, if required.
The combination product was provided as Simparica 
 Trio® chewable tablets in six different tablet strengths 
and was dosed at the dose ranges of 1.2 to 2.4 mg/kg 
sarolaner, 24 to 48 µg/kg moxidectin and 5 to 10 mg/kg 
pyrantel (as pamoate salt). The placebo tablets were pro-
vided in four different sizes. Treatments were adminis-
tered at monthly intervals on ten consecutive occasions 
on Days 0, 30, 60, 90, 120, 150, 180, 210, 240 and 270 
(with minor deviations). The dose was determined based 
on the bodyweight collected just before the treatment 
administration. Treatments were administered orally by a 
dedicated and unmasked dispenser and could be admin-
istered independently of the time of the dog’s main meal. 
Owners and masked clinic personnel performing clinical 
examinations and assessments were not allowed to wit-
ness the dispensing and the administration of the study 
treatments.
Dogs were presented to the clinics monthly on Days 
0, 30, 60, 90, 120, 150, 180, 210, 240, 270 and 300 (with 
minor deviations). At each clinic visit dogs received a 
physical examination by a veterinarian and blood sam-
ples were collected from each dog. Any abnormal health 
event observed by the examining veterinarian or reported 
by the dog owner was recorded, as were any concomi-
tantly administered medications. At each visit, serum 
samples were tested for A. vasorum antigen by masked 
study personnel using the Angio Detect™ Test (IDEXX 
Laboratories Inc., Westbrook, Maine, USA) in the clinic 
according to the manufacturer’s instructions. Additional 
serum samples were shipped to a single Central Labora-
tory (University of Zurich) where these were tested for 
circulating antigen and antibodies against A. vasorum 
using ELISAs according to the laboratory’s previously 
published protocols [26, 27].
If an animal tested positive with any or both of the 
antigen detection tests (ELISA or Angio Detect™ Test) 
Fig. 1 Locations of the study sites in Denmark (red markers) and Italy (blue markers)
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and was also positive for antibodies, then the animal 
was considered to be infected with A. vasorum. If only 
the antibody (by ELISA) or an antigen (either ELISA or 
Angio Detect™ Test, or both) test was positive, then three 
consecutive daily fecal samples, each weighing at least 
10 grams, were collected from the patient. These were 
processed with the modified Baermann method [11] in 
certified Parasitology Laboratories in each country (Uni-
versity of Copenhagen and University of Bari) to detect 
A. vasorum first-stage larvae (L1). If L1 were found in 
the feces (independent of the antibody and antigen test 
results), the animal was determined to be infected with 
A. vasorum. Any dog that was considered to be infected 
with A. vasorum subsequently received antiparasitic 
treatment for the condition.
Dogs that tested positive by the above-mentioned pro-
cedures on or before Day 60 were considered as having 
been infected before the beginning of the study and were 
withdrawn from the study. These dogs were excluded 
from the data analysis for efficacy but were included in 
the safety evaluation. Dogs that were considered to be 
infected with A. vasorum after Day 60 were included in 
the data analysis for efficacy and safety. The number and 
percentage of dogs infected with A. vasorum was tabu-
lated at each visit. Preventative efficacy was defined as 
the percent of animals that remained negative during the 
study in the Simparica  Trio®-treated group. All dogs that 
received at least one study treatment were included in 
the safety evaluation.
Survey study
The study was conducted as a prospective, observational 
clinical field survey. It was run concurrently with the pre-
vention study at the same study sites in Denmark and 
Italy. The aim was to determine the occurrence of natu-
ral A. vasorum infections in dogs in the same geographi-
cal areas as in the prevention study. The study was not 
intended to and thus was not designed to provide general 
prevalence data in the two countries, but to provide an 
estimation for the infection pressure that the study dogs 
enrolled in the prevention study were exposed to.
Dogs that needed to be tested for A. vasorum infection 
because the veterinarian considered them to be at risk 
of infection and/or were suspected to be infected were 
enrolled. During a single veterinary visit the demographic 
details of the dogs, their clinical signs and/or abnormal 
laboratory results and possible risk factors (e.g. dog was 
an active hunting dog or had history of eating snails or 
frogs, foxes have been seen in the area the dog is walked) 
were recorded. The study veterinarians were allowed to 
use any suitable diagnostic test to establish the diagno-
sis of A. vasorum infection. These methods included 
serological antigen detection test (Angio Detect™ Test), 
Baermann test using a single or three daily fecal sam-
ples, fecal smear and fecal flotation methods. The clinic 
staff was experienced in conducting and evaluating these 
tests. Once the veterinarian confirmed the diagnosis 
based upon the test results, the animal was considered 
positive for A. vasorum infection. To evaluate the infec-
tion pressure, the number and percentage of positive 
cases were determined for the entire study duration. To 
compare infected vs non-infected animals regarding the 
frequency distributions of the risk factors and diagnosti-
cally relevant clinical findings, Fisher’s Exact Test were 
conducted using the PROC FREQ procedure in SAS ver-
sion 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Prevention study
In total, 622 dogs of various breeds and mixed breeds 
were enrolled in the study, with 307 dogs receiving pla-
cebo and 315 dogs receiving Simparica  Trio®. Enroll-
ment by study site is summarized in Table 1. During the 
study, 45 placebo- and 46 combination product-treated 
dogs were lost to follow up or were withdrawn. Thus, 531 
dogs (262 placebo- and 269 combination product-treated 
dogs) completed the study on Day 300. Withdrawals 
included 32 dogs (20 dogs in the placebo group and 12 
dogs in the combination product group) that tested posi-
tive for A. vasorum before or on Day 60 and were thus 
considered to have been infected before enrollment.
The demographic data of the dogs in the two study 
groups were similar (see Table 2). During the study 2762 
doses of placebo and 2858 doses of Simparica  Trio® 
were administered. All dogs were dosed completely. Two 
dogs, one in each group, vomited after a single treatment 
administration and were re-dosed with a full dose. Both 
animals completed the study without further vomiting at 
any other administration.
None of the dogs in Simparica  Trio®-treated group 
tested positive during the study, while two placebo-
treated animals, both in Denmark, were diagnosed with 
an A. vasorum infection after Day 60. None of these two 
positive dogs showed any clinical signs of infection. One 
of the placebo-treated dogs (female Hovawart, 3-months-
old at enrollment and that was seen eating snails, living 
in an area where foxes were seen and in a household 
with history of A. vasorum infection) tested positive by 
the antibody ELISA at Days 92 and 119, and by antigen 
ELISA on Day 119. The Angio Detect™ Test was negative 
on Days 92 and 119. First-stage larvae were found in the 
feces collected on Days 109–111. The animal was treated 
with fenbendazole (25 mg/kg p.o.) for 20 days starting on 
Day 126, after which no L1 were found in the fecal sam-
ples collected on Days 148 to 150. The antibody ELISA 
was still positive on Day 150, while the antigen ELISA 
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and Angio Detect™ Test were negative. On Day 206, the 
dog tested negative by both ELISAs. The second placebo-
treated dog (2.5-year-old female Labrador retriever that 
lived in an area where foxes were seen) tested positive for 
antibodies by ELISA at Days 91, 120 and 154, but tested 
negative by the antigen ELISA and the Angio Detect™ 
Test on all these study days. First-stage larvae were found 
in the feces collected on Days 151 to 153. The animal was 
treated with milbemycin oxime (0.5 mg/kg p.o.) weekly 
for 4 weeks, starting on Day 157. There was no follow up 
information available from this animal after starting the 
treatment with milbemycin.
Of the dogs originally enrolled in the prevention study, 
34 dogs tested positive for A. vasorum. This included 
32 dogs that were positive before or on Day 60, and the 
two placebo-treated dogs that became infected during 
the study. Additionally, five more dogs tested positive at 
study screening and because they did not meet the inclu-
sion criteria, they did not receive any study treatment and 
were excluded from the study. Nevertheless, these dogs 
delivered information on the contemporaneously investi-
gated epidemiological situation within the study area and 
were thus included in the calculations of the total num-
ber of positive dogs in the prevention study. Therefore, 
Table 1 Enrollment per study site in the survey and the prevention study
Notes: For the survey study the total number of tested dogs and the number and percent of Angiostrongylus vasorum positive dogs is shown for each study site. For 
the prevention study the number and percent of all enrolled animals is provided per study site. Site DH withdrew from the studies
Country Study site ID Survey study Prevention study
All dogs A. vasorum positive Total
n n % n %
Denmark DA 50 19 38.0 31 5.0
DB 92 5 5.4 18 2.9
DD 15 0 0 9 1.4
DE 18 1 5.6 23 3.7
DF 23 2 8.7 29 4.7
DG 44 2 4.5 25 4.0
DH 1 0 0 0 0
DI 38 2 5.3 9 1.4
DJ 11 0 0 15 2.4
DK 10 5 50.0 9 1.4
DL 25 9 36.0 38 6.1
DM 52 1 1.9 37 5.9
DN 87 3 3.4 21 3.4
DO 42 7 16.7 13 2.1
DP 78 5 6.4 12 1.9
DR 22 6 27.3 30 4.8
Italy IA 83 5 6.0 23 3.7
IB 60 2 3.3 14 2.3
IC 82 5 6.1 20 3.2
ID 58 4 6.9 19 3.1
IE 82 12 14.6 25 4.0
IF 71 21 29.6 26 4.2
IG 79 15 19.0 38 6.1
IH 90 3 3.3 18 2.9
II 73 0 0 14 2.3
IJ 72 8 11.1 25 4.0
IK 49 9 18.4 17 2.7
IL 67 7 10.4 14 2.3
IN 82 29 35.4 30 4.8
IO 67 11 16.4 20 3.2
Total 1623 198 12.2 622 100
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during the entire study period, A. vasorum infection was 
diagnosed in 6.3% (39/622) of the dogs.
There were no adverse events related to treatment with 
Simparica  Trio® during the study. After the first treat-
ment administration 136 abnormal health events were 
reported in 74 dogs in the placebo-treated group (24.1%) 
and 187 events in 99 dogs in the Simparica  Trio®-treated 
group (31.4%). The abnormal health events were typical 
of those expected to occur in the general dog popula-
tion and occurred with similar frequency in both treat-
ment groups. The most frequent abnormal health events 
included skin and appendage disorders in 18.4% and 
24.1% of all events, digestive tract disorders in 21.3% and 
18.2% of all events, ear and labyrinth disorders in 11.0% 
and 11.8% of all events, in the placebo and the Simparica 
 Trio®-treated groups, respectively. Fourteen animals died 
or were euthanized during the 10-month study, seven 
animals in each group, none of which was related to treat-
ment administration. In the placebo-treated group 265 
dogs (86.3%) and in the Simparica  Trio®-treated dogs 162 
dogs (51.4%) received concomitant medications during 
the study. Overall, 84 and 90 unique concomitant medi-
cations were administered to the dogs in the placebo- 
and the Simparica  Trio®-treated group, respectively. 
Two placebo-treated and 3 Simparica  Trio®-treated dogs 
received anthelmintic treatments with efficacy against 
A. vasorum, therefore these dogs were withdrawn from 
the study after these treatments. In the placebo-treated 
group, the most commonly prescribed treatments were 
against flea/tick infestations in 37.3% of all concomitant 
medications in 224 dogs. In both groups deltamethrin 
collar was also frequently used in Italy for Leishmania 
spp. vector prevention, in 50 placebo-treated and 47 
Simparica  Trio®-treated dogs. Other frequently admin-
istered concomitant treatments included antibiotics, 
vaccines, non-steroidal anti-inflammatory medications, 
cestode treatment (praziquantel), sedatives, analgesics 
and anesthetics in animals of both groups, and anthel-
mintics (pyrantel) in the placebo-treated group.
Survey study
In total, 1623 dogs of various breeds and mixed breeds 
were enrolled, out of which 198 dogs tested positive for 
A. vasorum (see Table 1). The number of dogs tested at 
each study site and, therefore, the number and percent-
age of positive dogs varied across the different sites. 
Overall, in the tested dog population at the same study 
sites as in the prevention study 12.2% of the dogs were 
positive for A. vasorum during a 14-months study period.
The most commonly used diagnostic method in 77.7% 
of the dogs was the Angio Detect™ Test (n = 1261). Of 
all the 198 positive dogs, 155 dogs (78.3%) were diag-
nosed with this test. Baermann test with three daily 
fecal sampling was performed in 17.0% of the cases (n 
= 276) and with single fecal sampling in 5.2% of the 
dogs (n = 84). Of all the 198 positive dogs, 29 (14.6%) 
and 12 (6.1%) dogs were diagnosed using Baermann 
test on three daily or single fecal samples, respectively. 
One dog each was tested and found positive with fecal 
flotation and fecal smear.
The most common risk factor for the enrolled dogs 
(88.5% of the dogs) for A. vasorum infection was the 
presence of foxes in the area where the dogs lived, fol-
lowed by the history of eating snails/frogs in 61.7% 
(Table  3). Out of the 1623 study dogs, 61.6% (1000 
dogs) were enrolled by the study veterinarians because 
Table 2 Demographics of dogs enrolled in the survey and prevention studies
a Simparica  Trio® provided 1.2 to 2.4 mg/kg sarolaner, 24 to 48 µg/kg moxidectin and 5 to 10 mg/kg pyrantel (as pamoate salt) oral doses per kg body weight
Abbreviation: nd, not determined









Purebred (%) 1153 (71.0) 125 (63.1) 240 (78.2) 237 (75.2)
Non-purebred (%) 470 (29.0) 73 (36.9) 67 (21.8) 78 (24.8)
Age mean (years) 5.1 3.8 4.5 4.2
Age range (years) 0.1–16.0 0.1–14.0 0.2–15.0 0.2–13.0
Body weight mean (kg) nd nd 21.6 21.0
Body weight range (kg) nd nd 2.5–47.6 2.0–54.4
Male (%) 806 (49.7) 110 (55.6) 148 (48.2) 144 (45.7)
Female (%) 817 (50.3) 88 (44.4) 159 (51.8) 171 (54.3)
Lives mostly indoors (%) 106 (6.5) 8 (4.0) 10 (3.3) 11 (3.5)
Lives mostly outdoors (%) 609 (37.5) 106 (53.5) 120 (39.1) 125 (39.7)
Lives indoors and outdoors (%) 908 (55.9) 84 (42.4) 177 (57.7) 179 (56.8)
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they were suspected to be infected as they showed clin-
ical signs consistent with A. vasorum infection. Among 
the 198 dogs that tested positive for A. vasorum infec-
tion, 86.4% (n = 171) were suspected to be infected at 
enrollment based on their clinical signs, while these 
were absent in the remaining 13.6% of the animals. The 
clinical signs shown by all study dogs, dogs that tested 
positive or negative for A. vasorum infection, are listed 
in Table  3. Dogs positive for A. vasorum had signifi-
cantly more frequently a previous or ongoing history of 
an infection in the household, showed more frequently 
signs of respiratory disease (coughing, dyspnea, tachyp-
noea, increased lung sounds or crackles at ausculta-
tion, thoracic radiographic or ultrasonographic signs), 
bleeding disorders (including pale mucous membranes, 
petechiae or ecchymosis), exercise intolerance, syn-
cope, seizure, and tremor. Furthermore, also other signs 
(including weight loss, inappetence, lethargy, ascites, 
other neurological signs not listed in the table, melena, 
sneezing, heart murmur) and laboratory abnormalities 
(anemia, leukocytosis, thrombocytopenia, eosinophilia, 
hyperglobulinemia) were more frequently observed in 
A. vasorum positive dogs (see Table 3).
Discussion
The prevention study reported here demonstrated that 
a novel oral chewable tablet combining moxidectin, 
sarolaner and pyrantel provided complete preventative 
efficacy for dogs against A. vasorum infection under field 
conditions in endemic hot spots. The repeated monthly 
administrations of Simparica  Trio® for ten consecu-
tive months was well tolerated by the dogs. The infec-
tion pressure was substantial, with 6.3% of the total dogs 
Table 3 Potential risk factors and clinical signs reported in the survey study: in all enrolled dogs, and in the dogs that were positive or 
negative for Angiostrongylus vasorum infection
a P = the hypergeometric probability for the observed table (risk factor × A. vasorum status) for the Fisher’s exact test
b Two-sided p-value for Fisher’s exact test
c Anemia, leukocytosis, thrombocytopenia, eosinophilia, hyperglobulinemia
d Other signs included weight loss, inappetence, lethargy, ascites, melena, sneezing, heart murmur and other neurological signs not listed in the table
Note: P-values in bold font indicate significant differences between positive and negative animals
Category All dogs
(n = 1623)
Dogs positive for 
A. vasorum
(n = 198)




n % n % n % Pa/p-valueb
Risk factors
 History of eating snails/frogs 1001 61.7 117 59.1 884 62.0 0.0449/0.4360
 Active hunting dog 411 25.3 56 28.3 355 24.9 0.0404/0.3373
 Foxes seen in the area 1437 88.5 184 92.9 1253 87.9 0.0104/0.0422
 Previous history or ongoing A. vasorum infection in household 162 10.0 39 19.7 123 8.6 4.24×10−6/< 0.0001
Clinical signs
 Coughing 812 50.0 115 58.1 697 48.9 0.0033, 0.0185
 Dyspnea 358 22.1 61 30.8 297 20.8 0.0006/0.0024
 Tachypnoea 290 17.9 48 24.2 242 17.0 0.0039/0.0171
 Increased lung sounds at auscultation or crackles 356 21.9 79 39.9 277 19.4 4.36×10−10/< 0.0001
 Bleeding disorder 84 5.2 31 15.7 53 3.7 1.27×10−9/< 0.0001
 Pale mucous membranes 160 9.9 54 27.3 106 7.4 1.73×10−14/< 0.0001
 Petechiae or ecchymosis 55 3.4 25 12.6 30 2.1 3.42×10−10/< 0.0001
 Exercise intolerance 449 27.7 100 50.5 349 24.5 1.62×10−13/< 0.0001
 Syncope 48 3.0 15 7.6 33 2.3 0.0002/0.0003
 Seizure 44 2.7 11 5.6 33 2.3 0.0087/0.0164
 Tremor 51 3.1 11 5.6 40 2.8 0.0224/0.0484
 Blindness 20 1.2 5 2.5 15 1.1 0.0591/0.0862
 Thoracic radiographic or ultrasonographic signs 159 9.8 54 27.3 105 7.4 1.27×10−14/< 0.0001
 Diarrhea 145 8.9 13 6.6 132 9.3 0.0516/0.2338
 Vomiting 156 9.6 26 13.1 130 9.1 0.0208/0.0930
 Laboratory  abnormalitiesc 179 11.0 54 27.3 125 8.8 3.44×10−12/< 0.0001
 Other  signsd 104 6.4 34 17.2 70 4.9 7.16×10−9/< 0.0001
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screened and enrolled in the prevention study testing 
positive, and 12.2% of the selected dogs in the concurrent 
survey also testing positive. These results showed that the 
prevention study was conducted in endemic hot spots of 
A. vasorum, thus indicating that the dogs had high para-
site exposure. Nevertheless, due to the nature of the study 
it cannot be excluded entirely that dogs included in the 
prevention study did not ingest the parasite. The number 
of positive animals was expected to be high in the tested 
geographic locations: in fact, in the study areas in Den-
mark, a previous survey reported 14.0% prevalence in 
dogs with clinical signs consistent with A. vasorum infec-
tion [28]. In Italy, in a very recent survey with randomly 
selected dogs, 3.4% were infected with A. vasorum, with 
prevalence peaks of 5.8% to 19.3% in certain regions [29].
While effective treatment options are available for 
canine angiostrongylosis, clinical diagnosis is not always 
straightforward. Infected dogs may present with only 
vague signs affecting a variety of organ systems, includ-
ing most often the respiratory, but also the nervous, the 
cardiovascular and the gastrointestinal system, or may 
show only coagulopathies [21–24]. In the current sur-
vey with selected dogs, respiratory signs were the most 
frequently reported abnormality in the infected animals 
(e.g. coughing in 58.1% of the dogs), followed by exer-
cise intolerance in 50.5% of the dogs. Accordingly, also 
further signs indicative for an impairment of the respira-
tory system such as dyspnea (30.8%), tachypnea (24.2%) 
and increased lung sounds (39.9%) were significantly 
more frequent in infected animals and complemented 
by abnormalities observed through diagnostic imag-
ing. These results are in line with previous case series 
from Denmark [22] and from southern England [21, 30] 
in which coughing was the most frequent sign (68.1%, 
65% and 54%, respectively), followed by dyspnea (23.2%, 
43% and 22%, respectively), exercise intolerance (15.6%, 
35% and 17%, respectively) and depression (21.9%, 48% 
and 22%, respectively). Among further primary com-
plaints, hemorrhagic disorders are a frequent cause of 
death; they may manifest with bleedings from different 
body localizations or as petechiae or ecchymosis [21, 
24]. This was also more frequently observed in the group 
of infected dogs in the present study; they showed pale 
mucous membranes, petechiae or ecchymosis or melena, 
and corresponding laboratory findings such as anemia 
and thrombocytopenia. Hemorrhages were observed in 
15.6%, 35% and 15% of the dogs in the above-mentioned 
studies from Denmark and England as well [21, 22, 30]. 
Other laboratory findings more frequently observed in 
infected dogs of our studies (leukocytosis, eosinophilia, 
hyperglobulinemia) can be explained by the substantial 
inflammatory reaction that occurs during A. vasorum 
infections [31, 32]. Other unspecific signs such as weight 
loss, inappetence or lethargy that were more frequently 
reported in infected dogs of this study have been previ-
ously reported in A. vasorum infected dogs [21, 22], evi-
dencing the challenging clinical picture of the infection. 
However, infected dogs may not present with any clinical 
signs for a prolonged period and therefore the diagno-
sis may only be made at an advanced stage when severe 
damage is already present in the lungs. In line with this, 
in the survey study presented here, 13.6% of the dogs that 
tested positive for A. vasorum were not suspected to be 
infected by the veterinarian because they had no clinical 
signs. Previous or ongoing history of an infection in the 
household may alert and help to identify further positive 
dogs, as observed here.
In advanced cases, fatalities may occur before anthel-
mintic treatment can be initiated [21, 23, 33]. Regular 
preventative treatment is therefore the safest and most 
effective option for animals living in endemic areas 
and is recommended by the European Scientific Coun-
sel Companion Animal Parasites [34]. Before starting 
the prophylactic treatment regimen, it may be recom-
mended to test the dogs for concurrent infections.
In the prevention and survey studies different diagnos-
tic methods were used. In the survey study the aim was 
to establish the level of infection by the methods that are 
routinely used by veterinarians. Therefore, it was at the 
discretion of the veterinarians to diagnose the infection 
in the study dogs by the test method they were utiliz-
ing in their daily practice. Because the prevention study 
used a negative control group that was not allowed to 
receive any preventative treatment against A. vasorum 
during the study period, it was essential for animal wel-
fare reasons to diagnose an infection as early as possible. 
The ELISA methods were reported to be the most sensi-
tive tests to diagnose an early infection, hence these were 
implemented in the prevention study [26, 27]. These also 
showed best diagnostic consistency during the course 
of infection, compared to the Baermann method and to 
PCR performed with different substrates [35]. In experi-
mentally infected animals, antibodies can be detected by 
ELISA as early as 2 to 3 weeks, and at the latest between 
5 and 7 weeks after inoculation, i.e. this method may 
already detect infection during the prepatent period 
[27]. With a reported sensitivity of 85.7%, the antibody 
ELISA appears to be the most reliable test available for 
identifying dogs at an early stage of infection [27]. The 
antigen ELISA may require a longer time after infec-
tion to yield positive results. In experimentally infected 
dogs, the earliest positive results in 20% of the samples 
were observed 5 weeks post-inoculation when the fecal 
tests were still negative for L1 [26]. At 8–9 weeks after 
inoculation, 63.3–71.0% of the samples were antigen pos-
itive by ELISA [26, 36]. In comparison, with the Angio 
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Detect™ Test, the earliest positive results in experimen-
tally infected dogs were observed 9 weeks after inocula-
tion and it was only 5 weeks later when all samples were 
positive [35]. In that study L1 were detectable in the feces 
of the dogs 47–55 days after infection, indicating that 
positive results with the Angio Detect™ Test may only be 
expected in dogs with more advanced stages of infection, 
i.e. several weeks after a patent infection. In the survey 
study, the ELISA methods were not used, therefore it is 
possible that the study somewhat underestimated the 
number of positive animals, as dogs in the pre-patent 
period of infection could not be diagnosed.
In the prevention study, two placebo-treated dogs 
became infected during the study. These dogs were first 
positive by antibody ELISA 91 and 92 days (~13 weeks) 
after study start. As discussed above, the antibody ELISA 
is expected to become positive within 2–7 weeks after 
the infection took place, therefore these results indicate 
that these two animals became infected after study start. 
Because the antigen ELISA and the Angio Detect™ Test 
may detect infections at a later stage, it is not surprising 
that the antigen ELISA was only positive in one of the 
two dogs, and only when L1 were also detectable in the 
feces, while the Angio Detect™ Test was still negative in 
both dogs. This suggests that the two placebo dogs were 
indeed at an early stage of infection. The sensitivity of 
these tests should also be considered when interpreting 
the results. For the Angio Detect™ Test 84.6% (95% CI: 
69.5–94.1%) sensitivity and for the antigen ELISA 94.9% 
(95% CI: 82.7–99.3%) sensitivity was reported [36].
The preventative efficacy of Simparica  Trio® for angios-
trongylosis has recently been confirmed in placebo-con-
trolled, randomized, masked laboratory studies where 
dogs were experimentally infected with A. vasorum [37]. 
Simparica  Trio®, besides preventing angiostrongylosis, 
also provides effective treatment of flea and/or tick infes-
tations due to the inclusion of sarolaner [38, 39] and, due 
to pyrantel and moxidectin inclusion, efficacy against 
four gastrointestinal nematode species [40]. Additionally, 
the 24–48 µg/kg moxidectin dose in the combination is 
effective in the prevention of heartworm disease caused 
by Dirofilaria immitis [41]. Therefore, for dogs at risk of 
A. vasorum infection, Simparica  Trio® will provide an 
effective, safe and convenient option to prevent angios-
trongylosis and treat and protect against other important 
parasitic and potentially zoonotic infections at the same 
time.
Conclusions
Monthly oral treatment with the combination of 
sarolaner, moxidectin and pyrantel was safe and 100% 
effective in the prevention of natural infections with A. 
vasorum in dogs in high endemic areas with a concur-
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